Xenon Pharmaceuticals Inc (NASDAQ:XENE) shares rose 11.6% on Wednesday . The company traded as high as $17.40 and last traded at $17.18, approximately 553,058 shares changed hands during trading. An increase of 70% from the average daily volume of 324,642 shares. The stock had previously closed at $15.40.

XENE has been the topic of a number of recent research reports. ValuEngine lowered shares of Xenon Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, December 3rd. Zacks Investment Research upgraded shares of Xenon Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $16.00 price target on the stock in a research report on Saturday, January 11th. BidaskClub lowered shares of Xenon Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 4th. Finally, William Blair began coverage on shares of Xenon Pharmaceuticals in a report on Wednesday, January 8th. They issued an “outperform” rating on the stock. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. Xenon Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $19.67.

The company has a current ratio of 8.25, a quick ratio of 8.25 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $437.45 million, a price-to-earnings ratio of -11.99 and a beta of 1.50. The firm’s fifty day simple moving average is $15.31 and its two-hundred day simple moving average is $11.25.

Large investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC acquired a new position in Xenon Pharmaceuticals in the 3rd quarter valued at about $27,000. Bank of America Corp DE acquired a new position in Xenon Pharmaceuticals in the 4th quarter valued at about $34,000. Morgan Stanley boosted its holdings in Xenon Pharmaceuticals by 25.3% in the 2nd quarter. Morgan Stanley now owns 6,148 shares of the biopharmaceutical company’s stock valued at $61,000 after purchasing an additional 1,241 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in Xenon Pharmaceuticals by 66.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,006 shares of the biopharmaceutical company’s stock valued at $65,000 after purchasing an additional 2,004 shares during the last quarter. Finally, Supplemental Annuity Collective Trust of NJ acquired a new position in Xenon Pharmaceuticals in the 3rd quarter valued at about $99,000. Institutional investors own 69.17% of the company’s stock.

Xenon Pharmaceuticals Company Profile (NASDAQ:XENE)

Xenon Pharmaceuticals, Inc engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P.

Recommended Story: How Do You Make Money With Penny Stocks?

Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.